Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) is expected to issue its quarterly earnings data before the market ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

In ESSENCE, 37% of people treated with semaglutide saw an improvement in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo at the 72-week timepoint. Meanwhile ...